EMEA-002631-PIP01-19-M01
Key facts
Active substance |
Tapotoclax
|
Therapeutic area |
Oncology
|
Decision number |
P/0123/2022
|
PIP number |
EMEA-002631-PIP01-19-M01
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of acute myeloid leukaemia
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Amgen Europe B.V
Tel.: +44 (0)1223 420305 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|